NCT02371174 is a clinical trial in Breast Cancer, sponsored by Eisai Co., Ltd..

Who is sponsoring NCT02371174?

NCT02371174 is sponsored by Eisai Co., Ltd..

What condition does NCT02371174 study?

NCT02371174 studies Breast Cancer, HER2-negative Breast Cancer.

Is NCT02371174 still recruiting?

NCT02371174 is currently completed. Last updated 13 July 2018.

Last reviewed 2018-07-13 · How we verify

NCT02371174

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.

Completed Last updated 13 July 2018

What this trial tests

trial in Breast Cancer in 651 participants. Completed in 21 January 2018.

Timeline

3 September 2014

Primary endpoint
21 January 2018

21 January 2018

Quick facts

Lead sponsor	Eisai Co., Ltd.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	651
Start date	3 September 2014
Primary completion	21 January 2018
Estimated completion	21 January 2018
Sites	2 locations across Japan

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
HER2-negative Breast Cancer — all drugs for HER2-negative Breast Cancer →

Sponsor

Eisai Co., Ltd. — full company profile →

Who can join

Eligibility, female only, with Breast Cancer or HER2-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of the study is to clarify factors affecting the incidence of peripheral neuropathy in patients treated with HALAVEN. A total of 590 patients will be enrolled in this study with 295 patients in the treatment group of primary or secondary chemotherapy and 295 patients in the treatment group of tertiary or later chemotherapy.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Eribulin in Cancer Treatment.
Swami U, Shah U, Goel S. · · 2015 · cited 46× · PMID 26262627 · DOI 10.3390/md13085016
Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting.
Inoue K, Takahashi M, Mukai H, Yamanaka T, et al · · 2020 · cited 15× · PMID 31950374 · DOI 10.1007/s10637-019-00890-5
Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan.
Takahashi M, Inoue K, Mukai H, Yamanaka T, et al · · 2021 · cited 12× · PMID 33677779 · DOI 10.1007/s12282-021-01232-1
Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.
Tsurutani J, Sakata Y, Matsuoka T. · · 2019 · cited 11× · PMID 30324551 · DOI 10.1007/s12282-018-0919-8
Prognosis of Invasive Lobular Carcinoma and Effectiveness of Eribulin in Clinical Practice: A Post Hoc Analysis of a 2-Year Post-Marketing Surveillance.
Tanabe Y, Inoue K, Takahashi M, Mukai H, et al · · 2025 · cited 1× · PMID 40404608 · DOI 10.1111/ajco.14189

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Eisai Co., Ltd. trials

Trials by the same sponsor.

NCT07515014 — A Study of E6742 in Participants With Systemic Lupus Erythematosus · Phase 2 · not yet recruiting
NCT06793709 — A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast G · recruiting
NCT06657378 — A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized T · recruiting
NCT06322667 — A Post Marketing Study in Participants With Early Alzheimer's Disease Treated With Lecanemab · recruiting
NCT05633108 — A Study Based on the French National Health Insurance Database in Participants With Psychotic Disorders · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02371174 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eisai Co., Ltd.
Last refreshed: 13 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02371174.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing